Table 1.
No. | Age | Sex | Neurofibrillary changesa | Amyloida | Classification |
---|---|---|---|---|---|
1 | 22 | M | 0 | 0 | Non-pathological controls |
2 | 49 | F | 0 | 0 | |
3 | 70 | F | 0 | 0 | |
4 | 77 | M | 0 | 0 | |
5 | 21 | F | I | 0 | Minimal tau pathology |
6b | 49 | F | I | 0 | |
7 | 71 | F | I | 0 | |
8 | 88 | F | I | 0 | |
9 | 92 | M | II | 0 | Maximal tau pathology without concurrent amyloid |
10 | 60 | M | V | C | Alzheimer’s disease |
11 | 77 | F | V | C | |
12 | 87 | M | V | B | |
13 | 85 | F | VI | C | |
14 | 52 | F | VI | C | Down’s syndrome |
15 | 59 | M | VI | C | |
16 | 43 | M | 0 | B | High amyloid burden without concurrent tau pathology |
17 | 44 | F | 0 | B | |
18 | 56 | M | 0 | A | |
19 | 63 | M | 0 | B |
aStaging of neuropathology according to Braak and Braak [4]; amyloid stages: A, low density of deposits in isocortex with no involvement of hippocampus; B, medium density of deposits in isocortex with mild involvement of hippocampus; C, high density of deposits in isocortex with mild involvement of hippocampus. All cases were stage 0 synucleinopathies
bSubject died with sepsis